Cefpirome Sulfate for Injection Application Scope

Cefpirome Sulfate for Injection is mainly used for various types of acute leukemia, malignant lymphoma (including Hodgkin’s lymphoma), breast cancer, bronchial lung cancer, ovarian cancer, nephroblastoma, soft-tissue sarcoma, bladder cancer, testicular cancer, gastric cancer, medullary thyroid carcinoma, and prostate cancer.

cefpirome sulfate for injection

Cefpirome Sulfate for Injection Characteristics

Ingredient: Epimedicine

Characteristics: Treatment of multi-tumor cancer diseases

Specification: 10 mg

Storage: Shielded from light and kept sealed.

Execution standard: State Drug License H20000496

Revision date: According to the latest drug specification.

Manufacturer: Pfizer Pharmaceuticals

Guidelines For The Use Of Cefpirome Sulfate for Injection

Dosage and administration: The adult dose of epirubicin is 60~90mg/m2 at a time according to the body surface area when used alone, and 50~60mg/m2 intravenously at a time when used in combination with chemotherapy. It may be repeated at 21-day intervals depending on the patient’s blood picture.

Adverse reactions: common for alopecia (about 70; 80% of patients), myelosuppression (about 50; 60%, leukocytes can fall to the lowest point in 10 to 14 days after the use of the drug, and most of the gradual recovery in about 3 weeks, anemia and obvious thrombocytopenia is rare), loss of appetite, nausea, vomiting, but in the comparable dose of adriamycin, but the extent of its compared with adriamycin, the degree of its less than the adriamycin.

Medication Limitations

Contraindications: Potential teratogenic, mutagenic, and carcinogenic effects in animals, but lack of clear evidence in humans. Epirubicin, like Zorubicin and Adriamycin, crosses the placenta. Epirubicin is contraindicated during the first trimester of pregnancy and should not be used in lactating women.

Precautions: Cardiac function should be closely monitored during epirubicin therapy to minimize the risk of heart failure (this heart failure can occur even weeks after termination of therapy and may be ineffective in response to the appropriate drug therapy) The potential risk of cardiotoxicity of epirubicin may be increased in patients who are currently receiving or have previously received combined mediastinal and pericardial area radiotherapy. Caution should be exercised in determining the maximum accumulative dose of epirubicin when co-administered with any potentially cardiotoxic drug.

Cefpirome Sulfate for Injection Interactions

Epirubicin may be used in combination with other antineoplastic agents, but the epirubicin dosage should be reduced. When used in combination, it should not be used in the same syringe. Inform your doctor of all medications you are using before starting treatment. Epirubicin should not be mixed with heparin for injection because they are chemically incompatible and may precipitate at certain concentrations.

Cefpirome Sulfate for InjectionApplications
Cefpirome Sulfate for Injection is mainly used in various types of acute leukemia, malignant lymphoma (including Hodgkin’s lymphoma), breast cancer, bronchopulmonary cancer, ovarian cancer, nephroblastoma, soft tissue sarcoma, bladder cancer, testicular cancer, gastric cancer, medullary thyroid carcinoma and prostate cancer.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine, China Drug Import and Export Wholesaler. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.